Live Breaking News & Updates on Lyra Therapeutics|Page 5

Stay updated with breaking news from Lyra therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lyra Therapeutics (NASDAQ:LYRA) Price Target Cut to $11.00 by Analysts at Bank of America

Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) had its target price lowered by equities research analysts at Bank of America from $12.00 to $11.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price target would indicate a potential upside of […] ....

United States , Perceptive Advisors , Vanguard Group Inc , Cantor Fitzgerald , Lyra Therapeutics Inc , Samsara Biocapital , Lyra Therapeutics Company Profile , Lyra Therapeutics , Get Free Report , Point Capital , Vanguard Group , Lyra Therapeutics Daily ,

Lyra Therapeutics (NASDAQ:LYRA) Price Target Cut to $11.00

Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) had its target price dropped by investment analysts at Bank of America from $12.00 to $11.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s price objective points to a potential upside of […] ....

United States , Goldman Sachs Group Inc , Tower Research Capital , Lyra Therapeutics Company Profile , Cantor Fitzgerald , Heritage Wealth Management Inc , Jpmorgan Chase Co , York Mellon Corp , Lyra Therapeutics Inc , Lyra Therapeutics , Get Free Report , Research Capital , Wealth Management , Sachs Group , New York Mellon Corp , Lyra Therapeutics Daily ,

Lyra Therapeutics (NASDAQ:LYRA) Price Target Cut to $11.00 by Analysts at Bank of America

Lyra Therapeutics (NASDAQ:LYRA – Free Report) had its price target trimmed by Bank of America from $12.00 to $11.00 in a research report released on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock. LYRA has been the subject of several other reports. HC Wainwright reiterated a buy rating and issued […] ....

United States , Tower Research Capital , Heritage Wealth Management Inc , Jpmorgan Chase Co , Cantor Fitzgerald , Lyra Therapeutics Inc , York Mellon Corp , Goldman Sachs Group Inc , Lyra Therapeutics , Free Report , Therapeutics Stock Down , Research Capital , Wealth Management , Sachs Group , New York Mellon Corp , Get Free Report , Lyra Therapeutics Daily , Nasdaq Lyra , Lower Price Target , Bank Of America Co ,

Lyra Therapeutics' (LYRA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lyra Therapeutics (NASDAQ:LYRA – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $12.00 target price on the stock. Separately, Cantor Fitzgerald reiterated an overweight rating on shares of Lyra Therapeutics in a research note on Friday, […] ....

United States , Goldman Sachs Group Inc , Jpmorgan Chase Co , York Mellon Corp , Lyra Therapeutics Inc , Tower Research Capital , Cantor Fitzgerald , Heritage Wealth Management Inc , Lyra Therapeutics Company Profile , Lyra Therapeutics , Free Report , Research Capital , Wealth Management , Sachs Group , New York Mellon Corp , Get Free Report , Lyra Therapeutics Daily ,